Intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm


Phase N/A Results


The overall incidence of angiographic vasospasm measured between the seventh and eleventh day following SAH was similar between the two groups, with arterial narrowing detected in 74.4% of placebo patients and 64.6% of rt-PA treated patients (p = 0.31). There was a trend toward lesser degrees of vasospasm in the rt-PA treated group. The rates for no or mild, moderate, and severe vasospasm were 69%, 16% and 15% in the rt-PA treated group, versus 42%, 35% and 23% in the placebo group (P = 0.07).